Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. While cirrhosis has historically been a prerequisite for imaging-based HCC diagnosis, emerging data suggest that patients with noncirrhotic chronic hepatitis C (CHC)—particularly those with sustained virologic response following antiviral therapy—remain at risk for HCC. This evolving clinical reality raises a critical question: Can the Liver Imaging Reporting and Data System (LI-RADS) be confidently applied in this population?
A recent multicenter retrospective study published in Radiology by An et al. directly addresses this gap. The authors evaluated the diagnostic performance of the LI-RADS LR-5 category—which denotes “definitely HCC”—in patients with noncirrhotic CHC. Using imaging data from a large Korean cohort, the study assessed whether standardized LI-RADS criteria maintain their reliability in a group historically excluded from imaging-based diagnostic algorithms.
Study Design and Methods
The study included CHC patients without cirrhosis, identified through consistent fibrosis staging based on the METAVIR classification. Imaging protocols included multiphasic contrast-enhanced MRI and CT scans reviewed under LI-RADS v2018 criteria. Final diagnoses were confirmed using histopathology or multidisciplinary consensus.
Patients were stratified by fibrosis stage, with subgroup analyses performed to evaluate the diagnostic performance of LR-5 in both F0–F2 and F3 (bridging fibrosis) subpopulations. The study’s robust design accounted for variations in institutional imaging practices and fibrosis severity.
Key Findings
The LR-5 category demonstrated high specificity and diagnostic accuracy in detecting HCC in noncirrhotic CHC patients, including those with early-stage fibrosis.
Diagnostic performance remained consistent across imaging modalities (MRI and CT), highlighting the robustness of the LR-5 designation when applied with standardized imaging protocols.
Importantly, the authors reported that applying LI-RADS in noncirrhotic patients could reduce unnecessary biopsies and expedite treatment initiation in high-risk individuals.
Clinical Implications
This study is among the first to validate LI-RADS in a noncirrhotic hepatitis C population, suggesting that advanced fibrosis may not be a strict prerequisite for reliable imaging-based HCC diagnosis. Given the rising number of patients with treated HCV and preserved liver architecture, these findings carry substantial implications for hepatology, oncology, and radiology practice.
By expanding the utility of LI-RADS, clinicians may be empowered to offer noninvasive, imaging-based HCC diagnosis in patients who previously required confirmatory biopsy. However, as the authors caution, prospective studies are warranted before guideline recommendations can be formally revised.
Teaching Points for Radiology Trainees
LI-RADS LR-5 retains high diagnostic performance even in noncirrhotic CHC patients.
Noninvasive diagnosis of HCC may be feasible in patients with bridging fibrosis or lower fibrosis stages.
Standardized imaging protocols and fibrosis staging are critical to extending LI-RADS utility beyond its traditional scope.
Conclusion
This landmark study marks a significant step in adapting imaging-based diagnostic tools to reflect changing patient demographics in the post-HCV-treatment era. As radiologists, hepatologists, and oncologists increasingly encounter CHC patients without cirrhosis, evidence supporting the use of LI-RADS in this setting provides a timely and clinically impactful paradigm shift.
References
